- Home
- MCVT vs IMRN Comparison
MCVT vs IMRN Comparison
Compare MCVT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- IMRN
- Stock Information
- Founded
- MCVT 2007
- IMRN 1994
- Country
- MCVT United States
- IMRN Australia
- Employees
- MCVT N/A
- IMRN N/A
- Industry
- MCVT Finance Companies
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MCVT Finance
- IMRN Health Care
- Exchange
- MCVT Nasdaq
- IMRN Nasdaq
- Market Cap
- MCVT 14.7M
- IMRN 15.0M
- IPO Year
- MCVT N/A
- IMRN N/A
- Fundamental
- Price
- MCVT $2.01
- IMRN $1.87
- Analyst Decision
- MCVT
- IMRN Strong Buy
- Analyst Count
- MCVT 0
- IMRN 1
- Target Price
- MCVT N/A
- IMRN $5.00
- AVG Volume (30 Days)
- MCVT 85.2K
- IMRN 7.4K
- Earning Date
- MCVT 11-15-2024
- IMRN 10-29-2024
- Dividend Yield
- MCVT N/A
- IMRN N/A
- EPS Growth
- MCVT N/A
- IMRN N/A
- EPS
- MCVT 0.04
- IMRN N/A
- Revenue
- MCVT $3,248,401.00
- IMRN $3,271,194.00
- Revenue This Year
- MCVT N/A
- IMRN N/A
- Revenue Next Year
- MCVT N/A
- IMRN N/A
- P/E Ratio
- MCVT $53.85
- IMRN N/A
- Revenue Growth
- MCVT N/A
- IMRN 171.67
- 52 Week Low
- MCVT $1.86
- IMRN $1.48
- 52 Week High
- MCVT $3.88
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- MCVT 36.49
- IMRN 22.09
- Support Level
- MCVT $1.86
- IMRN $2.66
- Resistance Level
- MCVT $2.02
- IMRN $2.73
- Average True Range (ATR)
- MCVT 0.15
- IMRN 0.21
- MACD
- MCVT -0.03
- IMRN -0.08
- Stochastic Oscillator
- MCVT 23.93
- IMRN 5.68
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.